Mohua Chakraborty Choudhury
Biographic Data
| ID | 9065141 |
|---|---|
| NAME | Mohua Chakraborty Choudhury |
| GIVEN NAMES | Mohua Chakraborty |
| FAMILY NAME | Choudhury |
| SIGNATURE | CHOUDHURY M C |
| AFFILIATIONS | Centre for Policy Research |
| ORCID | 0000-0001-6727-9702 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Newborn screening in Karnataka
Newborn screening (NBS) using dried blood spot (DBS) analysis is an important public health intervention to detect serious congenital disorders early, and reduce childhood mortality, and lifelong disabilities. While institutionalized for decades in high-income countries, NBS remains limited in low- and middle-income countries such as India. Despite recommendations in national child healthcare policies, few Indian states have adopted NBS. Even Kar…
Mapping the rare disease stakeholders in India
Rare diseases (RD) are not rare collectively, affecting around 300 million people globally and 96 million in India. These diseases have not been prioritized in most low- and middle-income countries’ health policies. India launched its first functional RD policy in 2021. Successful policy implementation requires the active participation of diverse stakeholders. In the context of rare diseases, such collaboration has been particularly instrumental …
Assessment of the availability of repurposed orphan drugs in India
India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India’s patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs …
Rare disease patients in India are rarely involved in international orphan drug trials
We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversity, and to exclude such participants is to severely limit the diversity of any trial; (b) Even if a suitable drug for a rare disease is available in In…
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
Clinical trial registries such as ClinicalTrials.gov (CTG) hold large amounts of data regarding trials. Drugs for rare diseases are known as orphan drugs (ODs), and it is particularly important that trials for ODs are registered, and the data in the trial record are accurate. However, there may be discrepancies between trial-related data that were the basis for the approval of a drug, as available from Food and Drug Administration (FDA) documents…
No prominent works on this page.
Rare disease patients in India are rarely involved in international orphan drug trials
We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversity, and to exclude such participants is to severely limit the diversity of any trial; (b) Even if a suitable drug for a rare disease is available in In…
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
Clinical trial registries such as ClinicalTrials.gov (CTG) hold large amounts of data regarding trials. Drugs for rare diseases are known as orphan drugs (ODs), and it is particularly important that trials for ODs are registered, and the data in the trial record are accurate. However, there may be discrepancies between trial-related data that were the basis for the approval of a drug, as available from Food and Drug Administration (FDA) documents…
Assessment of the availability of repurposed orphan drugs in India
India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India’s patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs …
Newborn screening in Karnataka
Newborn screening (NBS) using dried blood spot (DBS) analysis is an important public health intervention to detect serious congenital disorders early, and reduce childhood mortality, and lifelong disabilities. While institutionalized for decades in high-income countries, NBS remains limited in low- and middle-income countries such as India. Despite recommendations in national child healthcare policies, few Indian states have adopted NBS. Even Kar…
Mapping the rare disease stakeholders in India
Rare diseases (RD) are not rare collectively, affecting around 300 million people globally and 96 million in India. These diseases have not been prioritized in most low- and middle-income countries’ health policies. India launched its first functional RD policy in 2021. Successful policy implementation requires the active participation of diverse stakeholders. In the context of rare diseases, such collaboration has been particularly instrumental …
Health Systems, Economic Evaluations, Quality of Life (4 works) · Bioinformatics (3 works) · Genomics and Rare Diseases (3 works) · Medicine (3 works) · Orphan drug (3 works) · Biology (2 works) · Clinical trial (2 works) · Disease (2 works) · Drug (2 works) · Health care (2 works)